At Stoic, we're a big believer in life sciences but know that breakthrough innovation is found in all domains of research. We come in early, looking to partner with founders at the pre-seed and seed stage. Stoicism is what we believe equips founders with the right toolbox to navigate the uncertainties and challenges of building a generational company. Stoic VC is a venture capital fund investing in emerging science and frontier technologies at the seed and pre-seed stage.
Location: Australia, New South Wales, Sydney
Employees: 1-10
Founded date: 2020
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series B
Portfolio 20
| Date | Name | Website | Total Raised | Location |
| 22.10.2025 | Ena Respir... | enarespiratory.com | $51.4M | Australia |
| - | lmplus.com.au | - | - | |
| - | OccuRx | occurx.com | - | - |
| - | BioScout | bioscout.com.au | $3M | Australia,... |
| - | Lenexa Med... | lenexamedical.com | $1M | Australia,... |
| - | Forcite He... | forcitehelmets.com | - | - |
| - | Exonate | exonate.com | $6.11M | United Kin... |
| - | Q-Sera | q-sera.com | - | - |
| - | Aurtra | aurtra.net | - | Australia,... |
| - | Kinoxis Th... | kinoxistherapeutics.com | - | Australia,... |
Show more
Mentions in press and media 2
| Date | Title | Description |
| 27.10.2025 | ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Clinical Studies of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections | Melbourne, Australia, 20 October 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing antivirals that enhance the body’s natural viral defence mechanisms to minimise the impact of symptomatic viral respiratory infectio... |
| 22.10.2025 | ENA Respiratory Raises US$22.4M in Series B Financing | ENA Respiratory, a Melbourne, Australia-based clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections, raised US$22.4m (AUD$34m) in Series B financ... |